[Form 4] Bicara Therapeutics Inc. Insider Trading Activity
Rhea-AI Filing Summary
Bicara Therapeutics Chief Financial Officer Hyep Ivan reported a series of transactions under a Rule 10b5-1 trading plan dated 02/13/2025. Between 10/06/2025 and 10/08/2025 the reporting person acquired option grants exercisable at $3.7898 and sold common stock in multiple trades. After the reported transactions the reporting person beneficially owned 145,355 shares of common stock.
The filings show three option grant vestings/exercises (total underlying shares: 30,385 across the three dates) with an exercise price of $3.7898 and expiration on 08/08/2033. Sales were executed at weighted average prices reported between approximately $18.15 and $18.36, and the filer offered to provide per-trade details on request.
Positive
- None.
Negative
- None.
Insights
Insider exercised low-cost options and sold shares under a pre-set plan.
The reporting person exercised stock options with an exercise price of $3.7898 and simultaneously sold shares at weighted average prices near $18.2, realizing a spread between exercise price and sale proceeds. The option vesting schedule is quarterly in sixteen equal installments beginning after 08/08/2023, which explains the staggered exercise and sale pattern.
This pattern is consistent with routine compensation monetization under a Rule 10b5-1 plan; monitor future Form 4 filings for additional option exercises, quarterly vesting amounts, and any changes to the trading plan timing.
Transactions were executed pursuant to a documented Rule 10b5-1 plan, reducing insider-timing risk.
The filing explicitly states the trades were made under a plan adopted on 02/13/2025, and the reporting person offered to disclose per-trade prices if requested. That disclosure supports procedural compliance and provides transparency about weighted-average sale prices between $18.15 and $18.36.
Items to watch include any amendments to the 10b5-1 plan or further sales/exercises reported on subsequent Form 4 filings, which would indicate ongoing monetization activity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 5,627 | $0.00 | -- |
| Exercise | Common Stock | 5,627 | $3.7898 | $21K |
| Sale | Common Stock | 5,627 | $18.208 | $102K |
| Exercise | Stock Option (Right to Buy) | 18,244 | $0.00 | -- |
| Exercise | Common Stock | 18,244 | $3.7898 | $69K |
| Sale | Common Stock | 18,244 | $18.2189 | $332K |
| Exercise | Stock Option (Right to Buy) | 6,514 | $0.00 | -- |
| Exercise | Common Stock | 6,514 | $3.7898 | $25K |
| Sale | Common Stock | 6,514 | $18.1695 | $118K |
Footnotes (1)
- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
